The purpose of this study is to determine if epcoritamab can be safely given without subjects needing to be admitted to the hospital (which usually means staying in the hospital overnight).
Learn more about the AbbVie M23-362 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
